Kiniksa Pharmaceuticals, Ltd. (KNSA) NASDAQ
46.92
-1.51(-3.12%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
46.92
-1.51(-3.12%)
Currency In USD
Address
Clarendon House
Hamilton, HM 11
United States of America (the)
Phone
7814399100
Website
Sector
Healthcare
Industry
Biotechnology
Employees
315
First IPO Date
May 25, 2018
| Name | Title | Pay | Year Born |
| Sanj K. Patel | Chief Executive Officer & Chairman of the Board | 2.24M | 1969 |
| Mark Ragosa | Executive VP & CFO | 1.08M | 1974 |
| Eben Tessari | Consultant | 1.13M | 1982 |
| John F. Paolini | Executive Vice President & Chief Medical Officer | 1.13M | 1965 |
| Ross Michael Moat | Executive VP, COO & Principal Operating Officer | 1.2M | 1980 |
| Mei Jang | Senior VP & Chief Technical Officer | 0 | N/A |
| Aaron Young | Chief Intellectual Property Officer | 0 | N/A |
| Jonathan Kirshenbaum | Investor Relations Officer | 0 | N/A |
| Michael R. Megna | Senior Vice President & Chief Accounting Officer | 0 | 1971 |
| Randy Perrin | Group Vice President & Global Medical Affairs | 0 | N/A |
| Martina Struck | Senior VP & Chief Regulatory Officer | 0 | N/A |
| Joseph Pirrello | Chief Business Officer | 0 | N/A |
| Douglas Barry | Senior Vice President, Chief Legal Officer & Secretary | 0 | N/A |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.